title: [Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice].
abstract: OBJECTIVE
  To investigate the effect of Endostatin and SU6668 combined with 5-FU on the growth and metastasis of human colon cancer in vivo and its mechanism.
  
  
  METHODS
  Metastatic model of human colon cancer was established by orthotopic implantation of human tumor tissue into colon wall of nude mice. Twelve days later, mice were randomly divided into saline water control, Endostatin, SU6668, Endostatin plus SU6668, and Endostatin plus SU6668 and 5-FU groups, intraperitoneal injected respectively every day for four weeks. Six weeks after implication, the tumor weight, inhibition rates, intratumoral microvessel density (MVD) and metastasis were evaluated after the mice were sacrificed.
  
  
  RESULTS
  Compared with the control, tumor growth was significantly inhibited in mice treated respectively with Endostatin, SU6668, Endostatin plus SU6668 and Endostatin plus SU6668 and 5-FU with an inhibition rate of 0, 64.9%, 63.5%, 76.4% and 88.2% respectively,and MVD decreased significantly in treated groups [(18.10+/-5.65) vs (2.75+/-0.75), (3.17+/-0.58), (0.94+/-0.42) and (0.36+/-0.45)]. The incidences of peritoneal and region lymph node metastases were significantly inhibited in Endostatin, SU6668, Endostatin plus SU6668 and Endostatin plus SU6668 and 5-FU (90% vs 16.7%, 25%, 0 and 0; 90% vs 0, 0, 0 and 0). The growth and metastasis of human colon cancer implanted in nude mice were significantly inhibited in Endostatin, SU6668, Endostatin plus SU6668, and Endostatin plus SU6668 and 5-FU, and the effect of Endostatin plus SU6668 and 5-FU was the most obviously.
  
  
  CONCLUSIONS
  Endostatin plus SU6668 and 5-FU has strong inhibitory effect both on tumor growth and metastasis of human colon cancer.
authors.affiliation: Department of General Surgery, Jiangxi Province People's Hospital, Nanchang, China. QLZKZ@163.com
authors.forename: Qing-Li
authors.initials: QL
authors.lastname: Zeng
authors.forename: Zhao-Hui
authors.initials: ZH
authors.lastname: Chu
authors.forename: Kai
authors.initials: K
authors.lastname: Zhou
authors.forename: Xiao-Jiang
authors.initials: XJ
authors.lastname: Luo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D043169:Endostatins / Q000627:therapeutic use*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D000078183:Oxindoles; D011422:Propionates; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D043169:Endostatins; D007211:Indoles; D000078183:Oxindoles; D011422:Propionates; D011758:Pyrroles; C412603:orantinib; D005472:Fluorouracil